Safety Assessment of an Anti-Obesity Drug (Sibutramine)A Retrospective Cohort Study

被引：0
|
作者：
Jerzy E. Tyczynski
Denise M. Oleske
David Klingman
Cheryl P. Ferrufino
Won Chan Lee
机构：
[1] Product Safety and Pharmacovigilance,Astellas Pharma Global Development, Inc.
[2] Global Surveillance and Pharmacoepidemiology,Abbott Laboratories
[3] Dept R4ED,Health Economics and Outcomes Research
[4] IMS Health Inc.,undefined
来源：
Drug Safety | 2012年 / 35卷 / 8期
关键词：
Acute Myocardial Infarction; Orlistat; Rimonabant; Sibutramine; Label Status;
D O I：
10.1007/BF03261960
中图分类号：
学科分类号：
摘要：
Background: Obesity is a serious and rapidly growing health problem worldwide. Few therapies are available beyond diet, exercise and bariatric surgery. A previously approved medication, sibutramine, has been withdrawn from the market due to concerns over the potential of increased risk of cardiovascular (CV) events, based on a phase IV clinical trial that included only individuals at high risk for CV events.
引用
收藏
页码：629 / 644
页数：15
相关论文
共 50 条
  • [31] Anti-obesity drugs: a review about their effects and their safety
    Derosa, Giuseppe
    Maffioli, Pamela
    EXPERT OPINION ON DRUG SAFETY, 2012, 11 (03) : 459 - 471
  • [32] Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment - Discussion
    Astrup
    Van Gaal
    Huth
    Cifkova
    Kelly
    James
    Po
    Hochlenert
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 1998, 106 : 39 - 40
  • [33] THE IMPACT OF APPROVED ANTI-OBESITY MEDICATIONS ON THE INCIDENCE OF CARDIOVASCULAR DISEASE, HEALTHCARE RESOURCE USE, AND COSTS AMONG PATIENTS WITH OBESITY: A RETROSPECTIVE COHORT STUDY
    Baser, O.
    Samayoa, G.
    Baser, E.
    Mohamed, M.
    VALUE IN HEALTH, 2024, 27 (12) : S64 - S65
  • [34] Anti-Obesity Drugs: A Review about Their Effects and Safety
    Kang, Jun Goo
    Park, Cheol-Young
    DIABETES & METABOLISM JOURNAL, 2012, 36 (01) : 13 - 25
  • [35] Evaluation of anti-obesity activity of duloxetine in comparison with sibutramine along with its anti-depressant activity: an experimental study in obese rats
    Chudasama, H. P.
    Bhatt, P. A.
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2009, 87 (11) : 900 - 907
  • [36] Anti-Obesity Agents and the US Food and Drug Administration
    Martin F. Casey
    Jeffrey I. Mechanick
    Current Obesity Reports, 2014, 3 (3) : 361 - 367
  • [37] Anti-Obesity Agents and the US Food and Drug Administration
    Casey, Martin F.
    Mechanick, Jeffrey I.
    CURRENT OBESITY REPORTS, 2014, 3 (03): : 361 - 367
  • [38] Chemogenomics-assisted anti-obesity drug discovery
    Hajjo, Rima
    Tropsha, Alexander
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
  • [39] An Efficient Process for The Synthesis of Anti-Obesity Drug Rimonabant
    Sarma, P. Seetharama
    Surayanarayana, M. V.
    Rao, Ch. Nageswar
    Reddy, Padi Pratap
    Khalilulah, M.
    Praveen, Cherukupally
    Chakravarthy, Akula Kalyan
    ASIAN JOURNAL OF CHEMISTRY, 2009, 21 (02) : 1171 - 1175
  • [40] Anti-obesity drug - Orlistat recommended for FDA approval
    不详
    SOUTH AFRICAN MEDICAL JOURNAL, 1997, 87 (07): : 853 - 853
12345